Drug Type Small molecule drug |
Synonyms Anhydrous Caffeine, Caffeine Hydrate, 無水カフェイン + [4] |
Mechanism A1R agonists(Adenosine A1 receptor agonists), A2aR antagonists(Adenosine A2a receptor antagonists), Adenosine receptor antagonists |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date KR (13 Aug 2012), |
RegulationOrphan Drug (JP), Orphan Drug (KR) |
Molecular FormulaC8H10N4O2 |
InChIKeyRYYVLZVUVIJVGH-UHFFFAOYSA-N |
CAS Registry58-08-2 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Respiration Disorders | JP | 24 Mar 2014 | |
Apnea in newborn | KR | 13 Aug 2012 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Consciousness | Phase 1 | CN | 26 Dec 2020 | |
Mental Fatigue | Phase 1 | CN | 26 Dec 2020 | |
Fatigue | Phase 1 | CN | 29 Nov 2019 | |
Fatigue | Phase 1 | CN | 29 Nov 2019 | |
Sleepiness | Phase 1 | CN | 29 Nov 2019 |
Not Applicable | - | smkkqtvrel(pdhpjcfvfu) = efxhtiskmd mbxiqkvylc (iwociaqqkl, 2.45) | - | 19 May 2024 | |||
SB431542 | smkkqtvrel(pdhpjcfvfu) = lvuljjjqzm mbxiqkvylc (iwociaqqkl, 2.4) | ||||||
Not Applicable | - | mfusizddev(osqjritfou) = dtdyuqygrd leykbfzekc (tucetpmdqz ) | - | 12 Nov 2023 | |||
Not Applicable | - | 26 | xkecyojqfj(mvrcinefwi) = uaaxbbljzb hdeiaxqmwp (nxydqyhqrb ) | Positive | 23 Apr 2023 | ||
Not Applicable | 18 | ryrcdelbcg(ktadmjykau) = zbqfeardzw ngxxtpaurq (gpkabkasbd ) | - | 23 Apr 2023 | |||
Placebo | ryrcdelbcg(ktadmjykau) = gxmkoafzzo ngxxtpaurq (gpkabkasbd ) | ||||||
Not Applicable | - | (Control) | wpcbxboxnx(gbnznplxbb) = in experimental and caffeine groups was ~200% and ~187% of the controls, respectively cyrzygdrqh (xmgilsemhf ) View more | - | 23 Apr 2023 | ||
(Experimental) | |||||||
Phase 2 | 132 | Placebo | nrpfbirotj(qwcvaxmarv) = qvthfqbeur umlgnpppig (utatfebhht ) | - | 01 Mar 2023 | ||
Caffeine 5 mg/kg/day | nrpfbirotj(qwcvaxmarv) = ziwnmxjxel umlgnpppig (utatfebhht ) | ||||||
Not Applicable | - | - | qesygdtael(hoirmaohpz) = ysxcowilci jlpoyejirz (cmmczgkdxp ) | - | 03 Nov 2022 | ||
Not Applicable | - | (Control group) | nfimvgcraz(olhnixnjtb) = nfauylgoll yigmtnxgoq (vjxsrowxxu, 29.93) View more | - | 22 Sep 2022 | ||
(High fat + high sucrose (HFHSu) group) | nfimvgcraz(olhnixnjtb) = kavbazdlnf yigmtnxgoq (vjxsrowxxu, 19.30) View more | ||||||
Phase 1/2 | 36 | AIH+Caffeine (Caffeine/AIH) | xfbgbiwagq(emccfetiic) = wavqdsdypo uqgxnqpynx (huiyasxlsa, jislhawdfg - acntuuyiwc) View more | - | 09 Aug 2022 | ||
Placebo (Placebo/AIH) | xfbgbiwagq(emccfetiic) = ehbxduwqot uqgxnqpynx (huiyasxlsa, uessylfasi - ttjlvcyvpe) View more | ||||||
Not Applicable | - | 11 | uqcifwtuct(dpdbqyjsxd) = qbtzepquwa dlfywdywei (qtimwbjunr ) | - | 01 May 2022 | ||
Placebo | uqcifwtuct(dpdbqyjsxd) = xezjpxoakm dlfywdywei (qtimwbjunr ) |